专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明授权

US09592271B2 Angiopoietin-based interventions for treating cerebral malaria 有权
标题翻译：促血液生成素治疗脑疟疾的干预措施
公开(公告)号：US09592271B2
公开(公告)日：2017-03-14
申请号：US14529677
申请日：2014-10-31
申请人： Regeneron Pharmaceuticals, Inc. , University Health Network
发明人： Lisa Arleen Purcell Ngambo , Sarah J. Higgins , Kevin C. Kain
IPC分类号： A61K38/16 , A61K38/17 , A61K38/18 , A61K39/395 , C07K16/22 , A61K45/06 , A61K31/357 , A61K31/365 , A61K31/49 , C07K14/515 , A61K39/00
CPC分类号： A61K38/1891 , A61K31/357 , A61K31/365 , A61K31/49 , A61K38/16 , A61K38/17 , A61K38/18 , A61K38/1866 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K14/515 , C07K16/22 , C07K2319/30 , Y02A50/386 , Y02A50/412 , A61K2300/00
摘要： The present invention provides methods for treating, preventing or reducing the severity of cerebral malaria. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a modified angiopoietin molecule such as AngF1-Fc-F1.
摘要翻译：本发明提供了治疗，预防或降低脑疟疾严重程度的方法。本发明的方法包括向有需要的受试者施用治疗有效量的包含修饰的血管生成素分子例如AngF1-Fc-F1的药物组合物。

72. 发明申请

US20170029515A1 METHOD OF INHIBITION OF LEUKEMIC STEM CELLS 审中-公开
标题翻译：抑制白血病干细胞的方法
公开(公告)号：US20170029515A1
公开(公告)日：2017-02-02
申请号：US15233260
申请日：2016-08-10
申请人： CSL Limited , University Health Network
发明人： John Edgar Dick , Liqing JIN , Gino Luigi VAIRO , David Paul GEARING , Samantha Jane BUSFIELD
IPC分类号： C07K16/28 , C07K16/30 , A61K31/7068 , A61K45/06 , A61K39/395
CPC分类号： C07K16/2866 , A61K31/7068 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2300/00 , C07K16/3061 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/567 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/76
摘要： A method for inhibition of leukemic stem cells expressing IL-3Rα (CD123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3Rα (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule.
摘要翻译：抑制表达IL-3Rα（CD123）的白血病干细胞的方法包括使细胞与包含Fc区或具有增强的Fc效应子功能的修饰的Fc区的抗原结合分子接触，其中所述抗原结合分子选择性结合IL- 3Rα（CD123）。本发明包括通过向患者施用有效量的抗原结合分子来治疗患者的血液癌症状况。

73. 发明申请

US20160361391A1 REDUCTION OF TRAF1 LEVELS COMBINED WITH NUTRIENT STRESS FOR TREATING LYMPHOCYTE-RELATED CANCERS 审中-公开
标题翻译：减少与治疗淋巴相关癌症的营养应激相结合的TRAF1水平
公开(公告)号：US20160361391A1
公开(公告)日：2016-12-15
申请号：US15121563
申请日：2015-03-06
申请人： THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO , UNIVERSITY HEALTH NETWORK
发明人： Ali Abdul Sater , Ann Josephine McPherson , Tania Helen Watts , Mark Minden , Rob Laister
IPC分类号： A61K38/46 , C12N15/113 , G01N33/574 , A61K31/7088
CPC分类号： A61K38/465 , A61K31/7088 , A61K31/713 , A61K38/50 , A61K45/06 , C12N15/1137 , C12N2310/122 , C12N2320/31 , C12Y305/01001 , C12Y305/03001 , G01N33/502 , G01N33/57407 , G01N33/57426 , G01N2333/525 , A61K2300/00
摘要： The present disclosure provides methods and uses for treating lymphocyte related cancers comprising administering a nutrient stress-inducing agent in combination with an agent that lowers the levels of or inhibits TRAF1. Also provided are methods of determining treatment for a subject with a lymphocyte related cancer and assays for identifying a PKN1 inhibitor.
摘要翻译：本公开提供了治疗淋巴细胞相关癌症的方法和用途，包括与降低TRAF1水平或抑制TRAF1的药剂组合施用营养应激诱导剂。还提供了确定具有淋巴细胞相关癌症的受试者的治疗方法和用于鉴定PKN1抑制剂的测定法。

74. 发明申请

US20160340403A1 METHODS AND COMPOSITIONS FOR PRODUCING A CELL EXPRESSING A T CELL RECEPTOR 审中-公开
标题翻译：用于产生细胞表达T细胞受体的方法和组合物
公开(公告)号：US20160340403A1
公开(公告)日：2016-11-24
申请号：US15111639
申请日：2015-01-28
申请人： UNIVERSITY HEALTH NETWORK
发明人： NAOTO HIRANO , MUNEHIDE NAKATSUGAWA , TOSHIKI OCHI
IPC分类号： C07K14/725 , C12N15/10
CPC分类号： C07K14/7051 , A61K38/00 , C12N15/1037 , C12N15/1055
摘要： Provided is a method for determining a TCR polypeptide chain that can form a TCR specific for a peptide of interest. Also provided are methods and compositions for producing a cell expressing a T cell receptor (TCR) specific for a peptide of interest, methods and compositions for producing a TCR chain nucleic acid and/or pair of TCR chain polypeptides and/or nucleic acids encoding a TCR, a cell population comprising the cell harboring the nucleic acids encoding a TCR obtained by said method, and a method for treating a disorder comprising administering to the subject said cell population.
摘要翻译：本发明提供了一种确定可形成感兴趣肽特异性TCR的TCR多肽链的方法。还提供了用于产生表达对感兴趣的肽特异性的T细胞受体（TCR）的细胞的方法和组合物，用于产生TCR链核酸和/或一对TCR链多肽和/或编码 TCR，包含携带编码通过所述方法获得的TCR的核酸的细胞的细胞群，以及用于治疗病症的方法，包括向受试者施用所述细胞群体。

75. 发明申请

US20160271230A1 AGENTS DIRECTED AGAINST A CIS RGMA/NEOGENIN INTERACTION OR LIPID RAFTS AND USE OF THE SAME IN METHODS OF TREATMENT 审中-公开
标题翻译：针对CIS RGMA / NEOGENIN相互作用或脂质过敏的药剂及其在治疗方法中的应用
公开(公告)号：US20160271230A1
公开(公告)日：2016-09-22
申请号：US14915492
申请日：2014-08-06
申请人： UNIVERSITY HEALTH NETWORK (UHN): TECHNOLOGY DEVELOPMENT AND COMMERCIALIZATION
发明人： Philippe P. MONNIER , Nardos G. TASSEW
IPC分类号： A61K38/44 , C07K16/28 , G01N33/50 , A61K31/137 , A61K31/495 , A61K38/17 , A61K31/724
CPC分类号： A61K38/443 , A61K31/137 , A61K31/365 , A61K31/495 , A61K31/7048 , A61K31/724 , A61K38/177 , A61K38/482 , A61K2039/505 , C07K14/435 , C07K14/705 , C07K16/28 , C07K2317/30 , C07K2317/76 , C12Y101/03006 , G01N33/5058 , G01N33/53 , G01N2333/4703
摘要： Disclosed herein is an agent that modulates a cis interaction between Repulsive Guidance Molecule A (RGMa) and Neogenin or lipid rafts. Modulation by the agent may include blocking the cis interaction between RGMa and Neogenin and/or disrupting lipid rafts. In turn, this promotes neuronal cell survival and axon growth and/or regeneration. Also disclosed herein is a method of treating a disease in a subject in need thereof. The method may include administering the agent to the subject. Further disclosed herein is a method of identifying an agent that modulates the cis interaction between RGMa and Neogenin.
摘要翻译：本文公开了调节排斥导向分子A（RGMa）和新生物或脂质筏之间的顺式相互作用的试剂。试剂的调节可能包括阻断RGMa和Neogenin之间的顺式相互作用和/或破坏脂筏。反过来，这促进神经元细胞存活和轴突生长和/或再生。本文还公开了治疗有需要的受试者的疾病的方法。该方法可以包括向受试者施用该药剂。本文进一步公开的是鉴定调节RGMa和Neogenin之间的顺式相互作用的试剂的方法。

76. 发明申请

US20160258934A1 PROTEASOME INHIBITION ASSAY AND METHODS OF USE 有权
标题翻译：缓释抑制试验及使用方法
公开(公告)号：US20160258934A1
公开(公告)日：2016-09-08
申请号：US15028846
申请日：2014-10-10
申请人： UNIVERSITY HEALTH NETWORK , BECKMAN COULTER, INC.
发明人： Vincent T. SHANKEY , Sergei GULNIK , Lidice L. LOPEZ , David W. HEDLEY , Sue CHOW
IPC分类号： G01N33/50 , G01N15/14
CPC分类号： G01N33/5041 , C07K14/47 , C07K16/18 , C12Q1/37 , G01N15/14 , G01N33/4915 , G01N33/5011 , G01N33/5047 , G01N33/53 , G01N33/582 , G01N2015/008 , G01N2015/1006 , G01N2015/149 , G01N2333/4704 , G01N2440/14
摘要： Assays that can measure the effect of proteasome inhibitors on target cells in a biological sample are provided. The assays include evaluation of the effects of proteasome inhibitors on proteasome activity in cells in a biological sample.
摘要翻译：提供了可以测量蛋白酶体抑制剂对生物样品中靶细胞的影响的测定。测定包括蛋白酶体抑制剂对生物样品中细胞中蛋白酶体活性的影响的评估。

77. 发明申请

US20160251418A1 ANTI-TRANSTHYRETIN ANTIBODIES 审中-公开
标题翻译：抗转铁蛋白抗体
公开(公告)号：US20160251418A1
公开(公告)日：2016-09-01
申请号：US15009662
申请日：2016-01-28
申请人： Prothena Biosciences Limited , University Health Network
发明人： Yue Liu , Tarlochan S. Nijjar , Avijit Chakrabartty , Jeffrey N. Higaki
IPC分类号： C07K16/18
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
摘要翻译：本发明提供了特异性结合转甲状腺素蛋白（TTR）的抗体。抗体可用于治疗或预防与TTR积累或TTR沉积物积聚（例如，TTR淀粉样变性）相关的疾病或病症。抗体也可用于诊断TTR淀粉样变性和抑制或减少TTR的聚集，以及其他应用。

78. 发明授权

US09373159B2 Method and system for compressed sensing image reconstruction 有权
标题翻译：压缩感知图像重建方法与系统
公开(公告)号：US09373159B2
公开(公告)日：2016-06-21
申请号：US14409212
申请日：2013-06-18
申请人： University Health Network
发明人： Sayed Masoud Hashemi Amroabadi , Patrick R. Gill , Narinder S. Paul
IPC分类号： G06K9/00 , A61B6/00 , G06T5/00 , G01R33/561 , G06T11/00 , G06T7/00 , A61B6/03 , A61B5/055
CPC分类号： G06T5/001 , A61B5/055 , A61B6/03 , A61B6/501 , A61B6/5205 , G01R33/5611 , G06T7/0012 , G06T11/006 , G06T2211/424 , G06T2211/436
摘要： A Compressed Sensing (CS) based image reconstruction method and system is described herein which may be used to reduce the X-ray dose radiation in Computed Tomography (CT) or to decrease the scan duration in MR imaging (MRI). Methods and systems described herein may address problems that have hindered the clinical usage of CS, i.e. computation complexity and modeling problems. Using the described algorithm, high quality images may be recovered from undersampled data which may help to reduce the scan time and the exposed invasive radiations. Using the same set of data in conventional image reconstruction algorithms (e.g. Filtered Back Projection (FBP) in CT) may cause severe streak artifacts and may take significantly more time using Graphics Processing Units (GPU) and parallel clusters with the conventional CS-based methods. This method can be used other imaging modalities using Radon transform (such as C-Arm and electron tomography, for example).
摘要翻译：本文描述了基于压缩感测（CS）的图像重建方法和系统，其可以用于减少计算机断层扫描（CT）中的X射线剂量辐射或降低MR成像（MRI）中的扫描持续时间。本文描述的方法和系统可以解决阻碍CS的临床使用的问题，即计算复杂性和建模问题。使用所描述的算法，可以从欠采样数据中恢复高质量图像，这可能有助于减少扫描时间和暴露的侵入辐射。在传统的图像重建算法（例如CT中的滤光反投影（FBP））中使用相同的数据集可能会导致严重的条纹伪影，并且可能会花费大量时间使用图形处理单元（GPU）和并行集群与传统的基于CS的方法。该方法可以使用其他成像方式使用Radon变换（例如C-Arm和电子层析成像）。

79. 发明申请

US20160140300A1 METHOD AND SYSTEM FOR AUTOMATED QUALITY ASSURANCE AND AUTOMATED TREATMENT PLANNING IN RADIATION THERAPY 审中-公开
标题翻译：辐射治疗自动质量保证和自动治疗规划方法与系统
公开(公告)号：US20160140300A1
公开(公告)日：2016-05-19
申请号：US14898060
申请日：2014-06-12
申请人： UNIVERSITY HEALTH NETWORK
发明人： Thomas G. Purdie , Christopher James McIntosh , Igor Svistoun
IPC分类号： G06F19/00
CPC分类号： G16H50/20 , A61N5/103 , A61N5/1038 , A61N5/1048 , A61N2005/1041 , G06F19/3456 , G06F19/3481 , G16H10/60 , G16H40/20 , G16H50/70
摘要： Methods and systems for evaluating a proposed treatment plan for radiation therapy, for evaluating one or more delineated regions of interest for radiation therapy, and/or for generating a proposed treatment plan for radiation therapy. Machine learning based on historical data may be used.
摘要翻译：用于评估放射治疗计划的治疗计划的方法和系统，用于评估放射治疗的一个或多个所划定的感兴趣区域和/或用于产生用于放射治疗的拟议治疗计划。可以使用基于历史数据的机器学习。

80. 发明申请

US20160045511A1 KINASE INHIBITORS AND METHOD OF TREATING CANCER 有权
标题翻译：激酶抑制剂和治疗癌症的方法
公开(公告)号：US20160045511A1
公开(公告)日：2016-02-18
申请号：US14823057
申请日：2015-08-11
申请人： University Health Network
发明人： Peter Brent Sampson , Yong Liu , Sze-Wan Li , Bryan T. Forrest , Heinz W. Pauls , Louise G. Edwards , Miklos Feher , Narendra Kumar B. Patel , Radoslaw Laufer , Guohua Pan
IPC分类号： A61K31/5377
CPC分类号： C07D403/10 , A61K31/5377 , A61K45/06 , C07D231/56 , C07D403/04 , C07D403/14 , C07D413/14
摘要： The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
摘要翻译：本发明涉及由以下结构式表示的化合物及其药学上可接受的盐：由该结构式表示的化合物是激酶抑制剂，因此本文公开了用于治疗癌症的化合物。本文提供了结构式中变量的定义。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式